Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...

Novo Nordisk said it's going to reduce spending to make up for the sales shortfall. On a conference call with analysts, Novo Nordisk executives were quizzed about the threat from compounding ...

Novo Nordisk A/S Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and ...

Good day, and thank you for standing by. Welcome to the Q1 2025 Novo Nordisk A/S Earnings Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in the realm of rare disease. Over the weekend, Novo unveiled data from ...